About 8 results found for searched term "CEF3" (0.097 seconds)
Cat.No. | Name | Target |
---|---|---|
M5490 | Cefmenoxime HCl | Antibiotic |
Cefmenoxime hemihydrochloride, SCE-1365 hemihydrochloride | ||
Cefmenoxime, a potent inhibitor of Enterobacteriaceae, is a cephalosporin antibiotic that is administered intravenously or intramuscularly. | ||
M5499 | Cephradine | Antibiotic |
Cefradine; SQ-11436 | ||
Cephradine (Cefradine) is a broad-spectrum and orally active cephalosporin. Cephradine is active against both gram-positive and gram-negative pathogens. Cephradine is effective in eradicating most penicillinase-producing organisms. Cephradine blocks solar-ultraviolet induced skin inflammation through direct inhibition of TOPK. | ||
M19930 | Cefpiramide acid | Anti-infection |
Cefpiramide acid; Cefpiramido; Cefpiramidum; WY-44635; SM-1652 | ||
Cefpiramide (Cefpiramide acid, Cefpiramido, Cefpiramidum, WY-44635, SM-1652) is a pseudomonas-active cephalosporin with a broad spectrum of antibacterial activity. | ||
M22040 | CEF3 | Others |
CEF3 | ||
M53446 | CEF8, Influenza Virus NP (383-391) | Anti-infection |
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses. | ||
M53447 | CEF7, Influenza Virus NP (380-388) | Anti-infection |
CEF7, Influenza Virus NP (380-388) is a HLA-B*08 restricted influenza virus nucleoprotein epitope. | ||
M53535 | CEF14, EBV Rta Protein (28-37) | Anti-infection |
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37). | ||
M53536 | CEF19, Epstein-Barr Virus latent NA-3A (458-466) | Anti-infection |
CEF19, Epstein-Barr Virus latent NA-3A (458-466) is a single peptide epitope, YPLHEQHGM, representing residues 458-466 of the type 1 Epstein-Barr Virus (EBV) nuclear antigen 3A protein (B95.8 strain). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.